Drug Discovery

RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration

RIBOMIC has signed the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company (“AJU”), for RBM-007 licensing agreement for the indication of the exudative age-related macular degeneration in the territory of Korea and Southeast Asia (Singapore, Philippines, Thailand, Vietnam, Indonesia, Malaysia, Cambodia and Myanmar; hereinafter "the Territory").

Pfizer, BioNTech collaborate to develop vaccine for COVID-19

Pfizer has collaborated with Biopharmaceutical New Technologies (BioNTech) for the co-development of a potential COVID-19 vaccine.

AcelRx Pharmaceuticals to acquire Tetraphase Pharmaceuticals

AcelRx Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the execution of a definitive merger agreement to acquire Tetraphase Pharmaceuticals, Inc. (Tetraphase) in a stock for stock deal at an exchange ratio of 0.6303 shares of AcelRx for each share of Tetraphase, or approximately $14.4 million as of the close of trading on March 13, 2020, plus a contingent value right (CVR).

BioStem Life Sciences announces expansion; contract manufacturing capabilities, and research and development laboratory

BioStem Life Sciences, a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company") a leading life sciences company specializing in perinatal tissue-based allografts for use in regenerative therapies, today announced the buildout of a brand new R&D lab.

Can-Fite to explore the anti-coronavirus effects of piclidenoson in collaboration with Lewis Katz School of Medicine at Temple University

Can-Fite BioPharma, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, is entering into a collaborative research agreement with the Lewis Katz School of Medicine at Temple University, Philadelphia, USA.

Forty Seven, Rocket collaborate on new treatment for Fanconi Anemia

Forty Seven and Rocket Pharmaceuticals have entered into a research collaboration for evaluating a new treatment regimen in Fanconi Anemia, a rare paediatric disease.

Silverback Therapeutics raises $78.5m in oversubscribed Series B financing

Silverback Therapeutics (“Silverback”) (“the Company”), a private biopharmaceutical company pioneering a new class of immune-modulating ImmunoTAC drug conjugates targeting previously inaccessible disease pathways, today announced the close of an oversubscribed $78.5 million Series B financing round.

Brii Biosciences provides funding to Columbia University for research on COVID-19 and other coronaviruses

Brii Biosciences (“Brii Bio”) and Columbia University have entered into a memorandum of understanding through which Brii Bio will provide funding to support research to be conducted by investigators at the university and led by David Ho, M.D., founding scientific director of the Aaron Diamond AIDS Research Center and professor of medicine at the Vagelos College of Physicians and Surgeons.

Kuur Therapeutics launches to develop and commercialise off-the-shelf CAR-NKT cell therapies

Kuur Therapeutics announced the launch of its new business in partnership with Baylor College of Medicine and Baylor’s Center for Cell and Gene Therapy. Houston-based Kuur Therapeutics will advance the work of its predecessor, Cell Medica, to develop anti-cancer therapies using its innovative chimeric antigen receptor natural killer T cell (CAR-NKT) therapy platform.